Post-FDA approval of imetelstat for MDS, several treatment implementation gaps remain
Jessy Thomas, PharmD, of Geron Corporation, and colleagues presented the findings at the 2026 SOHO Annual Meeting.
MDS News
SOHO 2026
Myelodysplastic Syndromes
MDS News
SOHO 2026
Meetings / Conferences
Study identifies factors that predict response to imetelstat for MDS treatment
Rami Komrokji, MD, of the Moffitt Cancer Center in Tampa, Florida, and colleagues will present the findings at the 2026 SOHO Annual Meeting.
Acute Lymphoblastic Leukemia News
SOHO 2026
Leukemia
Acute Lymphoblastic Leukemia
Meetings / Conferences
News
TKI discontinuation possible in Ph+ ALL following treatment with blinatumomab and ponatinib
Guidelines recommend maintenance TKI monotherapy following remission, though data are limited regarding outcomes following TKI discontinuation. Researchers sought to evaluate long-term outcomes in
Leukemia
Acute Myeloid Leukemia
News
Chemotherapy-free ATO/ATRA regimen improves survival in APL, but patient age is a crucial factor
About half of patients (n=232; 51.5%) were treated with ATO/ATRA alone, while 86 (19.1%) underwent intensified therapy with chemotherapy in addition to ATO
Cellular Therapy
Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Indolent B-Cell Lymphomas
News
Liso-cel plus ibrutinib induces deep remissions in patients with relapsed or refractory CLL/SLL
William G. Wierda, MD, of the University of Texas MD Anderson Cancer Center, and colleagues, published the findings in Blood.
EHA 2026
Meetings / Conferences
Myeloproliferative Neoplasms
Primary Myelofibrosis
Post-transplant molecular monitoring could prompt preemptive intervention in patients with myelofibrosis
A study found that residual myeloproliferative neoplasm clones persisted after hematopoietic cell transplantation in patients with myelofibrosis, and this information enabled researchers to
EHA 2026
Myeloproliferative Neoplasms
Primary Myelofibrosis
Study identifies 4 clinically distinct myelofibrosis subtypes that have different survival prognoses
Andy Zeng, MD, PhD, of Princess Margaret Cancer Centre in Toronto, Canada, and colleagues presented the findings at the 2026 EHA Congress. The
EHA 2026
Meetings / Conferences
Multiple Myeloma
Study identifies new standard of care for relapsed or refractory MM in the second line and beyond
Results from the MONUMENTAL-3 study showed that the combination of talquetamab and daratumumab with or without pomalidomide (Tal-DP/Tal-D) significantly improved survival compared with
ASCO 2026
Aggressive B-Cell Lymphomas
News
Largest study of rare HHV8+ DLBCL identifies risk factors associated with poor survival
In the largest cohort study of the rare HHV8-positive diffuse large B-cell lymphoma, researchers found that age ≥60 years, higher Charlson-Deyo score, HIV-positive
ASCO 2026
Study finds mRNA COVID-19 vaccination is safe for patients receiving bispecific antibody treatment
The retrospective, propensity score-matched cohort study used TiNetX electronic health record data to identify adult patients with hematologic malignancies receiving bispecific antibody therapy.